Compare TotalEnergies SE (TTE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs GeneDx Holdings Corp — how do they compare? TotalEnergies SE trades at $86.62 (market cap $191.82B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: TotalEnergies SE is far larger — about 95× GeneDx Holdings Corp's market cap, and TotalEnergies SE pays a 4.93% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold TotalEnergies SE for 90 Days and GeneDx Holdings Corp for 19 Days on average.
| TTE | WGS | |
|---|---|---|
Market Cap | $191.82B | $2.02B |
Volume | 3,311,339 | 734,640 |
Sector | Energy | Health |
52-Week High | $93.60 | $167.51 |
52-Week Low | $57.39 | $34.51 |
Typical Hold Time | 90 Days | 19 Days |
Enterprise Value | $222.81B | $2.05B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 10.54 and P/S of 0.94. Recent earnings beat expectations in Q1 and Q2 2026, though revenue has declined from 2022 peaks. The company maintains a strong cash flow profile and has announced a $10 billion investment in Argentina, alongside a commitment to grow dividends by 5% annually through 2030.
The outlook is supported by strategic expansions in LNG and power, but risks include volatile energy prices and execution of capital projects. Analyst consensus is bullish with a $95.33 price target, implying potential upside. Investors should weigh the company's solid fundamentals and shareholder returns against sector-specific headwinds and macroeconomic sensitivity.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
